KRAS and colorectal carcinoma: It was interesting to observe that, except the last two, all other pathways were less methylated (indicated by negative delta beta) for CRC tissue and the magnitude of hypo-methylation (although very minimum) was significantly greater in tumors with the KRAS mutation (indicated by the ANOVA interaction p-value).